Live·Open questions in longevity research
Questions

хочу придумать терапию для улучшения функционального состояния кожи людей среднего возраста до состояния молодых людей

Can repeated skin treatment help drug-resistant cells grow faster?

The question as the research states itCan repeated removal of abnormal skin cells accelerate growth of drug-resistant cell families, including after treatment stops?

A reduction in visible lesions measures a different outcome from the later growth of abnormal cell families. Under the proposed mechanism, treatment removes susceptible cells, surviving resistant cells expand during repair, and abnormal tissue returns despite the early improvement.

The whole reason

If that sequence occurred, judging treatment solely by early clearance could miss a later adverse effect. If it did not occur, treating recurrence as proof that treatment selected resistant cells would wrongly attribute a mechanism that had not been demonstrated. The supplied material does not connect either outcome to the question's ten-year cancer-risk requirement.

The question in full

The question concerns whether repeated treatment can reduce visible skin damage while leaving surviving abnormal cells better able to spread. It asks whether an antimetabolite, a drug that interferes with processes needed for cell growth, repeatedly removes susceptible cells and leaves resistant cell families to occupy the treated skin. The comparison is whether those resistant families expand faster because of repeated treatment, both between courses and after treatment stops, and whether the effect occurs consistently. The question assumes an initial reduction in lesions and proposes that competition during skin repair and cells surviving within hair follicles could reverse that early benefit; the supplied evidence does not establish this sequence.

Competing hypotheses

These hypotheses propose different mechanisms. Comparing their predictions helps identify observations that could distinguish them.

  1. 01Genetic material from killed skin cells may drive drug resistance and regrowth in survivorsIn skin keratinocytes with impaired p53 control, inherited genetic material from killed cells could drive most extra growth after repeated antimetabolite treatment. Removing acquired sequences should erase added resistance and growth; acceleration explained entirely by survivors’ original traits would reject this account.
  2. 02Repeated treatment may select resistant cell lineages that cross a threshold for sustained growthIn reconstructed skin, repeated treatment may select initially rare resistant cell lineages whose production of self-renewing basal cells exceeds losses after withdrawal. Baseline samples should predict survival and faster repopulation; failure to predict it alongside functional donor DNA would favor a rival.
Each entry represents a published hypothesis. Where no hypotheses are published yet, the entries show possible answers to the scientific question.

What results would tell us about the hypotheses

Choose a possible result to see which hypothesis it would support, what the alternatives predict, and what would need to be tested next.

If we observe
В потомстве нескольких независимо помеченных выживших линий появятся последовательности погибших донорских клонов с подтверждёнными участками включения в геном. Новые сочетания будут сохраняться после удаления препарата и повторного выращивания клеток в общей контрольной среде. Удаление приобретённого участка должно одновременно устранять дополнительную лекарственную устойчивость и ускорение роста. Если ускорение полностью объясняется исходными свойствами выживших линий либо исчезает после смены среды, гипотеза уступает соответственно Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth или another hypothesis of the same gap. Одного обнаружения чужой ДНК внутри клетки недостаточно. Hypothetical result
Would support the hypothesis
Genetic material from killed skin cells may drive drug resistance and regrowth in survivors — In skin keratinocytes with impaired p53 control, inherited genetic material from killed cells could drive most extra growth after repeated antimetabolite treatment. Removing acquired sequences should erase added resistance and growth; acceleration explained entirely by survivors’ original traits would reject this account.
Other hypotheses predict
  • Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth — Параллельно сохранённые образцы исходных линий позволят предсказать, какие из них переживут повторные курсы и дадут ускоренное заселение. После переноса одинакового числа выживших клеток в свежую контрольную модель преимущество сохранится, но скорость размножения отдельной линии будет совпадать с её скоростью до лечения. При плавном изменении измеренного отношения рождения и утраты базальных клеток вероятность длительного сохранения линии резко изменится около критической области, а время угасания увеличится при приближении к ней снизу. Отсутствие прогностической силы исходных свойств при появлении функциональной донорской ДНК поддержит Genetic material from killed skin cells may drive drug resistance and regrowth in survivors; перенос ускорения бесклеточной средой поддержит another hypothesis of the same gap.
What to check next
Does repeated antimetabolite treatment accelerate the expansion of resistant abnormal skin cell families between courses and after treatment stops?

These are hypothetical results. Selecting one shows what would follow from it; it does not confirm a hypothesis or change its assessment.

Comparing hypotheses

Compare the proposed mechanisms, the predictions that distinguish the hypotheses, and the observations that would count against each one.

01

Genetic material from killed skin cells may drive drug resistance and regrowth in survivors

Horizontal somatic inheritance
Proposed mechanism

In skin keratinocytes with impaired p53 control, inherited genetic material from killed cells could drive most extra growth after repeated antimetabolite treatment.

Full text

Проверяемая гипотеза: повторное уничтожение атипичных кератиноцитов создаёт поток генетического материала, который выжившие клетки с нарушенным контролем p53 могут включать в собственный геном. Приобретённые последовательности образуют новые сочетания с исходными изменениями клетки и повышают одновременно её устойчивость к антиметаболиту и способность размножаться после отмены. Сильное утверждение этой гипотезы состоит в том, что горизонтальное наследование объясняет большую часть дополнительного роста после повторных курсов. Носителем долговременного изменения служит приобретённая ядерная ДНК. Предотвращение её функционального закрепления должно ограничивать связанный с лечением компонент SPV_11.

What distinguishes its prediction

В потомстве нескольких независимо помеченных выживших линий появятся последовательности погибших донорских клонов с подтверждёнными участками включения в геном.

Full text

Новые сочетания будут сохраняться после удаления препарата и повторного выращивания клеток в общей контрольной среде. Удаление приобретённого участка должно одновременно устранять дополнительную лекарственную устойчивость и ускорение роста. Если ускорение полностью объясняется исходными свойствами выживших линий либо исчезает после смены среды, гипотеза уступает соответственно IH_Q_L3_M_G4_1_02 или IH_Q_L3_M_G4_1_03. Одного обнаружения чужой ДНК внутри клетки недостаточно.

What would weaken the hypothesis

Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth predicts instead: Параллельно сохранённые образцы исходных линий позволят предсказать, какие из них переживут повторные курсы и дадут ускоренное заселение.

Full text

После переноса одинакового числа выживших клеток в свежую контрольную модель преимущество сохранится, но скорость размножения отдельной линии будет совпадать с её скоростью до лечения. При плавном изменении измеренного отношения рождения и утраты базальных клеток вероятность длительного сохранения линии резко изменится около критической области, а время угасания увеличится при приближении к ней снизу. Отсутствие прогностической силы исходных свойств при появлении функциональной донорской ДНК поддержит IH_Q_L3_M_G4_1_01; перенос ускорения бесклеточной средой поддержит IH_Q_L3_M_G4_1_03.

Бесклеточная среда, полученная после удаления препарата из модели с продолжающейся гибелью клеток, ускорит рост ранее не леченных контрольных линий. Эффект воспроизведёт измеренная концентрация простагландина E2, а блокирование его рецепторного действия на клетки-реципиенты устранит ускорение. При повторном выращивании выживших линий в свежей среде дополнительное преимущество исчезнет. Ускорение, сохраняющееся после прекращения гибели и продукции простагландина E2, опровергнет эту гипотезу как достаточное объяснение и поддержит наследуемые механизмы IH_Q_L3_M_G4_1_01 или IH_Q_L3_M_G4_1_02.

02

Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth

Population extinction criticality
Proposed mechanism

In reconstructed skin, repeated treatment may select initially rare resistant cell lineages whose production of self-renewing basal cells exceeds losses after withdrawal.

Full text

Проверяемая гипотеза: повторные курсы преимущественно сохраняют исходно редкие лекарственно устойчивые линии, у которых после отмены число новых самоподдерживающихся базальных клеток превышает число клеток, утрачиваемых вследствие гибели и окончательной дифференцировки. Популяция выживших пересекает порог между вероятным угасанием и устойчивым размножением. Поэтому абсолютное заселение после отмены ускоряется при неизменных свойствах каждой исходной линии. Состояние хранится в составе выживших линий, а порог определяется балансом клеточных судеб. Ограничение числа сохраняющихся сверхкритических линий должно стабилизировать связанный с лечением компонент SPV_11.

What distinguishes its prediction

Параллельно сохранённые образцы исходных линий позволят предсказать, какие из них переживут повторные курсы и дадут ускоренное заселение.

Full text

После переноса одинакового числа выживших клеток в свежую контрольную модель преимущество сохранится, но скорость размножения отдельной линии будет совпадать с её скоростью до лечения. При плавном изменении измеренного отношения рождения и утраты базальных клеток вероятность длительного сохранения линии резко изменится около критической области, а время угасания увеличится при приближении к ней снизу. Отсутствие прогностической силы исходных свойств при появлении функциональной донорской ДНК поддержит IH_Q_L3_M_G4_1_01; перенос ускорения бесклеточной средой поддержит IH_Q_L3_M_G4_1_03.

What would weaken the hypothesis

Genetic material from killed skin cells may drive drug resistance and regrowth in survivors predicts instead: В потомстве нескольких независимо помеченных выживших линий появятся последовательности погибших донорских клонов с подтверждёнными участками включения в геном.

Full text

Новые сочетания будут сохраняться после удаления препарата и повторного выращивания клеток в общей контрольной среде. Удаление приобретённого участка должно одновременно устранять дополнительную лекарственную устойчивость и ускорение роста. Если ускорение полностью объясняется исходными свойствами выживших линий либо исчезает после смены среды, гипотеза уступает соответственно IH_Q_L3_M_G4_1_02 или IH_Q_L3_M_G4_1_03. Одного обнаружения чужой ДНК внутри клетки недостаточно.

Бесклеточная среда, полученная после удаления препарата из модели с продолжающейся гибелью клеток, ускорит рост ранее не леченных контрольных линий. Эффект воспроизведёт измеренная концентрация простагландина E2, а блокирование его рецепторного действия на клетки-реципиенты устранит ускорение. При повторном выращивании выживших линий в свежей среде дополнительное преимущество исчезнет. Ускорение, сохраняющееся после прекращения гибели и продукции простагландина E2, опровергнет эту гипотезу как достаточное объяснение и поддержит наследуемые механизмы IH_Q_L3_M_G4_1_01 или IH_Q_L3_M_G4_1_02.

No test is published for this question yet

The hypotheses above state the observations that could distinguish them. A proposed experiment for this question has not yet been published.

What to check next: Does repeated antimetabolite treatment accelerate the expansion of resistant abnormal skin cell families between courses and after treatment stops?

Every proposed test

What the literature settles, and what it does not

The sources read against this question, the assumption it rests on, and the verdict that follows.

Can repeated removal of abnormal skin cells accelerate growth of drug-resistant cell families, including after treatment stops?

What this question is asking

The question concerns whether repeated treatment can reduce visible skin damage while leaving surviving abnormal cells better able to spread. It asks whether an antimetabolite, a drug that interferes with processes needed for cell growth, repeatedly removes susceptible cells and leaves resistant cell families to occupy the treated skin. The comparison is whether those resistant families expand faster because of repeated treatment, both between courses and after treatment stops, and whether the effect occurs consistently. The question assumes an initial reduction in lesions and proposes that competition during skin repair and cells surviving within hair follicles could reverse that early benefit; the supplied evidence does not establish this sequence.

What the terms mean
Antimetabolite
A class of drugs that interfere with chemical processes cells need to grow and reproduce. The question concerns whether repeated treatment with such a drug could favor surviving abnormal cells.
5-fluorouracil
The antimetabolite named in the supplied sources. Application to the skin and injection into a lesion are different treatment settings represented in those sources.
Abnormal or atypical cells
Cells with features that differ from the usual cells in the tissue. This broad description does not by itself establish that a cell is cancerous or resistant to treatment.
Clone or cell family
Cells descended from a shared original cell. Growth of a resistant clone means expansion of that family, rather than simply the return of a visible skin patch.
Drug resistance
Reduced susceptibility to a drug's effects. Failure of a treatment to clear a lesion does not by itself establish resistance in a particular cell family.
Lesion
An area of visibly or otherwise detectably abnormal tissue. Its disappearance and the disappearance of every abnormal cell are distinct outcomes.
Regenerative selection
The proposed process in which some surviving cell families gain an advantage as tissue repairs itself. In this question it is a suggested mechanism, not a finding established by the supplied sources.
Hair follicle or follicular reservoir
A hair follicle is the skin structure from which a hair grows. Calling it a reservoir proposes that cells survive there and later spread into surrounding skin; that role is not established here.
Repopulation
Cells expanding into an area after other cells have been removed. The question specifically concerns repopulation by resistant abnormal cell families.
Actinic keratosis
A skin lesion associated with sun damage that can be a precursor to skin cancer. It is the condition discussed in S1, S2, S4, and S5.
Topical and field-directed treatment
Topical treatment is applied to the skin surface. Field-directed treatment covers an affected area rather than targeting only an individual visible lesion.
Imiquimod
A skin-applied medicine named alongside 5-fluorouracil in the combination treatment described by S5. That combination's reported potential benefit does not identify why earlier treatment failed.
Squamous cell carcinoma
A cancer arising from cells that form surface linings, including the skin. S10 concerns an existing skin cancer, a different setting from prevention across an area of skin.
Biopsy
Removal and examination of a tissue sample. In S10, this examination provided the reported evidence of cancer clearance.
Recurrence
Return of a condition after it has cleared or improved. Recurrence alone does not reveal which cell family produced it or whether treatment caused resistance.
RL-3
An undefined label attached to antimetabolite prevention in the supplied gap detail. The input does not establish what treatment or evidence category it denotes.
What the question takes for granted
Premise could not be checked
Antimetabolite prevention produces mainly short-term clinical benefit, while regenerative selection and follicular reservoirs permit subsequent repopulation that could reverse the long-term effect of repeated courses.

The assumption is that treatment initially reduces visible abnormal skin patches, but surviving cell families gain a growth advantage as the skin repairs itself. Hair follicles, the structures from which hairs grow, are proposed as places where abnormal cells can survive and later spread back into treated skin. If established, this would explain how early improvement could coexist with a worse later outcome.

S10 reports clearance of one patient's cancer and no recurrence during five months of follow-up, establishing only a limited example of an early favorable outcome. S4 suggests that follow-up at six to twelve months might better assess treatment effectiveness and recurrence; it does not demonstrate that benefits are mainly short-lived. S1 and S2 identify established treatment options, while S5 discusses combination treatment after previous therapy failed. None of these supplied excerpts establishes selection of resistant cell families, survival within hair follicles, or reversal of long-term benefit. The evidence supplied is too limited to judge the full premise, and the label RL-3 is not defined.S1S2S4S5S10

The same question asked without the part nothing read establishes:

  • Does repeated antimetabolite treatment accelerate the expansion of resistant abnormal skin cell families between courses and after treatment stops?
  • How does abnormal skin cell growth after repeated antimetabolite treatment relate to the initial change in visible lesions?
What turns on the answer
  • Faster growth persists after treatment stops Under the proposed mechanism, susceptible cells disappear while resistant survivors expand during repair. If that faster expansion continues after treatment ends and occurs consistently, early lesion reduction would not establish lasting control of abnormal cells. An increase in cancer risk would still require separate evidence.
  • Faster growth occurs only between courses Repeated treatment would be associated with faster expansion of resistant survivors while courses continue, but that difference would disappear after treatment stops. This would support a treatment-period effect without establishing a lasting reversal of benefit.
  • Repeated treatment does not accelerate growth Removing susceptible cells would not translate into faster expansion of resistant cell families. Early improvement would therefore not be undermined by this particular mechanism, although lasting benefit and cancer risk would remain separate questions.
Why it matters

A reduction in visible lesions measures a different outcome from the later growth of abnormal cell families. Under the proposed mechanism, treatment removes susceptible cells, surviving resistant cells expand during repair, and abnormal tissue returns despite the early improvement. If that sequence occurred, judging treatment solely by early clearance could miss a later adverse effect. If it did not occur, treating recurrence as proof that treatment selected resistant cells would wrongly attribute a mechanism that had not been demonstrated. The supplied material does not connect either outcome to the question's ten-year cancer-risk requirement.

Could not be determined

The supplied evidence is too thin on the central mechanism to judge the proposed gap. S1 and S2 establish treatment context, S4 discusses follow-up timing, and S5 addresses treatment after previous failure. S10, although labeled partly_answers, reports only one patient's clearance and five-month absence of recurrence without measuring resistant cell families. The inference from these limitations is that neither accelerated repopulation nor its absence has been established; the search results cannot establish that the wider literature leaves the question unanswered.S1S2S4S5S10

What the literature establishes
  • S1 lists 5-fluorouracil among treatments applied across an area of skin affected by actinic keratosis.S1
  • S2 gives a strong recommendation for topical 5-fluorouracil in the management of actinic keratosis. That recommendation does not itself establish what happens to resistant cell families after repeated treatment.S2
  • S4 states that follow-up six to twelve months after treatment might better assess effectiveness and possible recurrence of actinic keratoses. This is a statement about assessment timing, not a finding that treatment accelerates recurrence.S4
  • The supplied abstract for S5 states that combined topical 5-fluorouracil and imiquimod may be effective when standard treatment for actinic keratoses has failed.S5
  • S10 describes one patient with squamous cell carcinoma whose repeat biopsy showed complete cancer clearance after the eighth weekly injection of 5-fluorouracil into the lesion. The patient remained free of recurrence during five months of follow-up.S10
What it does not settle
  • Whether repeated treatment selects resistant abnormal cell families or makes them expand faster between courses.
  • Whether abnormal cells survive in hair follicles and subsequently repopulate treated skin through the proposed mechanism.
  • Whether accelerated expansion occurs after treatment stops, how long it lasts, and whether it occurs consistently across patients or treatment episodes.
  • Whether early lesion reduction conceals a reversal of long-term benefit. S10's five-month observation does not establish the longer-term outcome.S10
  • The magnitude of any additional cancer risk over ten years, its relevance to middle-aged people, and its relationship to skin function remain unestablished. The input supplies no numerical bounds for acceptable cell growth or cancer risk.
Sources read · 5

4 literature searches, 6 full texts, 4 abstract-only; 10 source(s) assessed against this question using the available text. A bounded search is not evidence of absence.

S1Background

Current therapies for actinic keratosis. · International journal of dermatology · 2020

“Whereas, field-directed treatments are: (i) 5-fluorouracil (5-FU); (ii) diclofenac 3% gel; (iii) chemical peeling; (iv) imiquimod; and (v) photodynamic therapy (PDT).”

Does not settle: Источник не сообщает, приводит ли повторное применение антиметаболита к заселению кожи устойчивыми клонами после первоначального уменьшения поражений, и сохраняется ли или воспроизводится ли такой эффект после отмены лечения.

S2Background

Guidelines of care for the management of actinic keratosis. · Journal of the American Academy of Dermatology · 2021

“Conclusions: Strong recommendations are made for using ultraviolet protection, topical imiquimod, topical 5-fluorouracil, and cryosurgery.”

Does not settle: Источник не устанавливает, меняет ли повторное применение антиметаболита последующее заселение кожи устойчивыми клонами, сохраняется ли такой эффект после отмены и как он соотносится с первоначальным уменьшением поражений.

S4Background

Infrequent Follow-Up for Actinic Keratosis Treatment: A National Ambulatory Medical Care Survey. · The Journal of clinical and aesthetic dermatology · 2022

“Follow-up 6 to 12 months post-treatment might better assess efficacy and potential reoccurrence of AKs.”

Does not settle: Источник не изучает повторное применение 5-фторурацила, заселение кожи устойчивыми клонами, первоначальное уменьшение поражений или воспроизводимость эффекта после отмены лечения.

S5BackgroundAbstract only

Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study. · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2012

“In patients who have failed standard therapy for AKs, combination treatment using topical 5-FU and imiquimod cream may be an effective alternative therapeutic strategy.”

Does not settle: Источник не изучает повторное удаление клеток, последующее заселение кожи устойчивыми клонами, эффект отмены лечения или его воспроизводимость после отмены.

S10Partly answers it

Treatment of squamous cell carcinoma with intralesional 5-Fluorouracil. · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2003

“A repeat biopsy after the eighth treatment showed total clearance of the cancer, and the patient has remained free of recurrence during a 5-month follow-up period.”

Does not settle: Источник описывает одного пациента с плоскоклеточным раком кожи после восьми еженедельных внутриочаговых введений 5-фторурацила. Он не устанавливает, ускоряет ли повторное удаление атипичных клеток заселение кожи устойчивыми клонами, не оценивает такие клоны и не проверяет воспроизводимость эффекта после отмены лечения.

Every open question